Information Provided By:
Fly News Breaks for December 31, 2015
FLML
Dec 31, 2015 | 12:30 EDT
Roth Capital analyst Scott Henry says more competition is coming for Flamel Technologies' Bloxiver after West-Ward received FDA approval for a competitive product. The analyst expects the approval to impact Flamel's 2016 sales by $35M-$40M, resulting in a 40c hit to earnings per share. Henry believes, however, that Flamel shares are already pricing in West-Ward's approval and he keeps a Buy rating on the name with a $21 price target.
News For FLML From the Last 2 Days
There are no results for your query FLML